BIOKEY is a research organisation in Diepenbeek. Private Limited, started on 6 February 2019, 1 establishment.

What is the address of BIOKEY?

The registered office of BIOKEY is located at Agoralaan Abis, 3590 Diepenbeek.

Is BIOKEY still active?

Yes. According to the CBE (29 October 2026) BIOKEY is active, legal situation “Normale toestand”, started on 6 February 2019.

Is BIOKEY registered on Peppol?

Yes, BIOKEY is registered on the Peppol network with ID 0208:0719913808.

What is the enterprise number of BIOKEY?

The enterprise number of BIOKEY is BE0719913808.

When was BIOKEY founded?

BIOKEY was founded on 6 February 2019.

Who are the directors of BIOKEY?

According to the 2026 annual accounts, the directors of BIOKEY are: Jennifer Bath, Dirk Van Hyfte, Ingrid Brands.

Is BIOKEY a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 6 February 2019; 6 annual accounts filed, latest fiscal year 2026; 3 directors known from the annual account.

How much profit did BIOKEY make in 2026?

BIOKEY recorded a loss after taxes of € 16,912 in financial year 2026.

What is the revenue of BIOKEY?

As a small company, BIOKEY is not required to publish revenue in its annual accounts. In financial year 2026, its added value was € -16,079.

BIOKEY (Private Limited) - Diepenbeek - BE0719913808

Dossier BIOKEY, printed on 29 October 2026 from databakkes.be/en/0719913808/biokey. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Negative equity NBB

More debt than assets in 4 of the last 4 fiscal years.
Two loss years in a row NBB

Negative result in 2025 and 2026.
Tight liquidity NBB

Cash and receivables cover 2 % of short-term debt in 2026; threshold 65 %.
Busy address KBO

14 other companies have their registered office at the same address; threshold 10.

Financials

Financial year 2026

BIOKEY from Diepenbeek, company number BE0719913808, closed financial year 2026 with a result of € -16,912 after tax. For that financial year BIOKEY recorded a gross margin of € -16,079 and equity of € -220,187. Compared with financial year 2025, the result moved from € -26,728 to € -16,912. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on October 1, 2026.

What it is worth Caution

€ -220,187

▼ € 16,912 vs 2025

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -16,912

▲ 37 % less loss than in 2025

Profit after tax over the fiscal year.

Cash in the bank

€ 2,036

▲ 231% vs 2025

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -243,437.

Debts at end 2026

Bank debt

None

No bank loans on the last day of the fiscal year.

Key figures per fiscal year Download key figures (CSV)
	2023	2024	2025	2026	Change 2025 → 2026
Gross margin	€ -50,810 Gross margin 2023: € -50,810 First fiscal year in the series	€ -48,288 Gross margin 2024: € -48,288 ▲ € 2,522 vs 2023 (€ -50,810) Favourable step	€ -25,987 Gross margin 2025: € -25,987 ▲ € 22,301 vs 2024 (€ -48,288) Favourable step	€ -16,079 Gross margin 2026: € -16,079 ▲ € 9,908 vs 2025 (€ -25,987) Favourable step	▲ € 9,908
Profit after taxes	€ -54,899 Profit after taxes 2023: € -54,899 First fiscal year in the series	€ -48,865 Profit after taxes 2024: € -48,865 ▲ € 6,035 vs 2023 (€ -54,899) Favourable step	€ -26,728 Profit after taxes 2025: € -26,728 ▲ € 22,137 vs 2024 (€ -48,865) Favourable step	€ -16,912 Profit after taxes 2026: € -16,912 ▲ € 9,816 vs 2025 (€ -26,728) Favourable step	▲ € 9,816
Equity	€ -127,682 Equity 2023: € -127,682 First fiscal year in the series	€ -176,547 Equity 2024: € -176,547 ▼ € 48,865 vs 2023 (€ -127,682) Unfavourable step	€ -203,275 Equity 2025: € -203,275 ▼ € 26,728 vs 2024 (€ -176,547) Unfavourable step	€ -220,187 Equity 2026: € -220,187 ▼ € 16,912 vs 2025 (€ -203,275) Unfavourable step	▼ € 16,912
Total debts	€ 148,551 Total debts 2023: € 148,551 First fiscal year in the series	€ 182,129 Total debts 2024: € 182,129 ▲ 23% vs 2023 (€ 148,551) Unfavourable step	€ 205,205 Total debts 2025: € 205,205 ▲ 13% vs 2024 (€ 182,129) Unfavourable step	€ 222,793 Total debts 2026: € 222,793 ▲ 9% vs 2025 (€ 205,205) Unfavourable step	▲ 9%
Cash	€ 17,622 Cash 2023: € 17,622 First fiscal year in the series	€ 581 Cash 2024: € 581 ▼ 97% vs 2023 (€ 17,622) Unfavourable step	€ 616 Cash 2025: € 616 ▲ 6% vs 2024 (€ 581) Favourable step	€ 2,036 Cash 2026: € 2,036 ▲ 231% vs 2025 (€ 616) Favourable step	▲ 231%
Retained profit	€ -150,932 Retained profit 2023: € -150,932 First fiscal year in the series	€ -199,797 Retained profit 2024: € -199,797 ▼ € 48,865 vs 2023 (€ -150,932) Unfavourable step	€ -226,525 Retained profit 2025: € -226,525 ▼ € 26,728 vs 2024 (€ -199,797) Unfavourable step	€ -243,437 Retained profit 2026: € -243,437 ▼ € 16,912 vs 2025 (€ -226,525) Unfavourable step	▼ € 16,912
Balance sheet total	€ 20,869 Balance sheet total 2023: € 20,869 First fiscal year in the series	€ 5,582 Balance sheet total 2024: € 5,582 ▼ 73% vs 2023 (€ 20,869) Unchanged	€ 1,931 Balance sheet total 2025: € 1,931 ▼ 65% vs 2024 (€ 5,582) Unchanged	€ 2,606 Balance sheet total 2026: € 2,606 ▲ 35% vs 2025 (€ 1,931) Unchanged	▲ 35%

Key figures of BIOKEY, fiscal years 2023 to 2026, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2027) expected before 30 November 2027.

What happened to BIOKEY?

What happened at BIOKEY in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Oct 1, 2026 New annual accounts for financial year 2026: loss of € 16,912. Source: NBB ↗
2022 Jennifer Bath became a director. NBB
Feb 6, 2019 New establishment in Diepenbeek. KBO
2019 Dirk Van Hyfte became a director. NBB
2019 Ingrid Brands became a director. NBB
Feb 6, 2019 Start of the company according to the CBE. KBO

In short

From € 54,899 loss in 2023 to € 16,912 loss in 2026.

Original PDFs at the National Bank ↗

Management

IDEA FAMILY 80%

The stake of IDEA FAMILY comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

BIOKEY

Behind BIOKEY are Jennifer Bath, Dirk Van Hyfte and Ingrid Brands. The shares are held by IDEA FAMILY (80%).

Directors

According to the 2026 annual accounts

Jennifer Bath

Director

Also active at: IDEA FAMILY, BIOCLUE

since 2022

Dirk Van Hyfte

Director

Also active at: IDEA CONSULT, BIOCLUE

since 2019

Ingrid Brands

Director

Also active at: IDEA CONSULT, BIOCLUE

since 2019

Shareholders

IDEA FAMILY

80%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Agoralaan Abis

3590 Diepenbeek

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 14 companies are registered at this address.

All companies at this address →

Clinitude

€ 419,430 gross margin · 2025

FOx Biosystems

€ -763,895 gross margin · 2023

Highstar Engineering

€ -52,153 gross margin · 2025

IDEA FAMILY same network

€ -1,811 gross margin · 2026

BIOSTRAND

€ -3.7 million gross margin · 2026

+9 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0719.913.808

VAT number

BE 0719.913.808

Registered office

Agoralaan Abis, 3590 Diepenbeek

Names & denominations

BIOKEY

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

6 February 2019

Peppol

Active · Active since 5 Dec 2025

Activities · NACE

Speur- en ontwikkelingswerk op biotechnologisch gebied

Overige diensten op het gebied van informatietechnologie en computer

Overige zakelijke dienstverlening, neg

Ontwerpen van computerprogramma’s

Activiteiten van ingenieurs en aanverwante technische adviseurs, exclusief landmeters-experts

Activiteiten op het gebied van computerconsultancy en beheer van computerfaciliteiten

Computerconsultancy-activiteiten

View on CBE Public ↗ Annual accounts (NBB) ↗

BIOKEY

Warning lights

Financials

What happened to BIOKEY?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions